Scientific work

Doç. Dr. Seher Yıldız Tacar

32 publications. The source of the information is stated next to each publication.

Back to profile

  1. Consent architecture in biobanking: ethical attitudes and consent preferences among people with cancer and caregivers

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-17118-4 Open-access full textSource: OpenAlex

  2. Prognostic Value of BMI in Patients with Metastatic Cervical Cancer:A Retrospective Study From Turkey

    OncoTargets and therapy, 2026

    DOI 10.2147/ott.s622194 PMID 42644128 Open-access full textSource: Europe PMC

  3. Prognostic value of CT-measured baseline tumor volume in nivolumab-treated metastatic renal cell carcinoma

    Tumori, 2026

    DOI 10.1177/03008916261490843 PMID 42847292 Source: Europe PMC

  4. Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy

    Medicina, 2025

    DOI 10.3390/medicina61071168 PMID 40731799 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  5. Understanding of Clinical Trials Among Patients With Cancer and Their Relatives

    JAMA Network Open, 2025

    DOI 10.1001/jamanetworkopen.2024.57020 PMID 39874033 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  6. The Relationship Between Changes in the Neutrophil-Lymphocyte Ratio (NLR) and Radiological Progression in Cervical Cancer

    Istanbul Medical Journal, 2025

    DOI 10.4274/imj.galenos.2025.59254 Open-access full textSource: OpenAlex

  7. The Relationship Between Hemoglobin to Albumin Ratio and Disease-Free Survival in Patients with Locally Advanced Nasopharyngeal Cancer Treated with Chemoradiotherapy

    Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy, 2025

    DOI 10.4274/bmj.galenos.2025.2025.3-8 Open-access full textSource: OpenAlex

  8. Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?

    Current Oncology, 2024

    DOI 10.3390/curroncol31090384 PMID 39330012 Open-access full textSource: OpenAlex

  9. Alectinib-induced Non-immune Hemolytic Anemia due to Erythrocyte Membrane Alterations: A Retrospective Evaluation

    Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy, 2024

    DOI 10.4274/bmj.galenos.2024.2024.3-9 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  10. PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study

    Journal of Geriatric Oncology, 2023

    DOI 10.1016/j.jgo.2023.101604 PMID 37683369 10 citations (Europe PMC) Open-access full textSource: OpenAlex

  11. Awareness and perceptions of clinical trials in patients with cancer and their families in Turkey.

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.16_suppl.e18780 1 citation (OpenAlex) Source: OpenAlex

  12. Patient preferences for use of archived biospecimens in Turkey.

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.16_suppl.e18904 Open-access full textSource: OpenAlex

  13. Naples prognostic score may predict overall survival in metastatic pancreatic cancer

    Journal of Cancer Research and Therapeutics, 2023

    DOI 10.4103/jcrt.jcrt_1392_22 PMID 38554329 12 citations (OpenAlex) Open-access full textSource: OpenAlex

  14. Naples Score May Predict Overall Survival in Metastatic Gastric Cancer and is Superior to CONUT

    Acta Oncologica Turcica, 2023

    DOI 10.5505/aot.2023.80269 Open-access full textSource: OpenAlex

  15. Onkolojide Moleküler Hedefli Tedaviler

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1478 Open-access full textSource: OpenAlex

  16. Decrease in estimated glomerular filtration rates in non-small cell lung cancer patients treated with crizotinib

    Journal of Cancer Research and Therapeutics, 2022

    DOI 10.4103/jcrt.jcrt_1276_21 PMID 37313913 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  17. Crizotinib for c-MET-amplified advanced NSCLC: a single-center experience

    Tumori, 2022

    DOI 10.1177/03008916211009303 PMID 33849345 3 citations (Europe PMC) Source: Europe PMC

  18. Association of Low Muscle Mass as a Marker of Sarcopenia with Survival in Metastatic Renal Cell Carcinoma Patients Receiving Nivolumab

    Eurasian Journal of Medical Investigation, 2022

    DOI 10.14744/ejmi.2022.66227 2 citations (OpenAlex) Source: OpenAlex

  19. Nivolumab induced hypophysitis in an advanced RCC patient

    Journal of Oncology Pharmacy Practice, 2022

    DOI 10.1177/10781552211072212 PMID 35006033 3 citations (OpenAlex) Source: OpenAlex

  20. With metastatic colorectal cancer: A single center experience use of monoclonal antibodies (Bevacizumab, Cetuximab, and Panitumumab) in patients

    Journal of Experimental and Clinical Medicine, 2022

    DOI 10.52142/omujecm.39.4.34 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  21. Lutetium-Associated Myopathy: A Case Report

    American Journal of Therapeutics, 2022

    DOI 10.1097/mjt.0000000000001491 PMID 35383588 1 citation (OpenAlex) Source: OpenAlex

  22. Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer

    Istanbul Medical Journal, 2022

    DOI 10.4274/imj.galenos.2022.56804 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  23. Evaluation of predictive factors in patients with bladder cancer undergoing atezolizumab treatment

    Indian Journal of Cancer, 2022

    DOI 10.4103/ijc.ijc_160_21 PMID 36861522 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  24. Prosnostic Significance of Prognostic Nutrition Index in Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors

    Namık Kemal Tıp Dergisi, 2022

    DOI 10.4274/nkmj.galenos.2022.80764 Open-access full textSource: OpenAlex

  25. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study

    Melanoma Research, 2021

    DOI 10.1097/cmr.0000000000000744 PMID 34039945 16 citations (Europe PMC) Source: OpenAlex

  26. Thirty-day mortality rates after immunotherapy initiation

    Immunotherapy, 2021

    DOI 10.2217/imt-2021-0082 PMID 34676791 2 citations (Europe PMC) Source: Europe PMC

  27. Ribociclib induced acute kidney injury: A case report

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021

    DOI 10.1177/10781552211007202 PMID 33847193 12 citations (Europe PMC) Source: Europe PMC

  28. 976P The 30-day mortality rate after first cycle of immunotherapy

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.1360 Open-access full textSource: OpenAlex

  29. Onkolojik Aciller

    Akademisyen Kitabevi eBooks, 2021

    DOI 10.37609/akya.243 Source: OpenAlex

  30. Next generation sequencing analysis of BRCA1 and BRCA2 identifies novel variations in breast cancer

    Life Sciences, 2020

    DOI 10.1016/j.lfs.2020.118334 PMID 32846166 7 citations (OpenAlex) Source: OpenAlex

  31. SP788EFFECTS OF IL-1β RECEPTOR ANTAGONIST IN KIDNEY TRANSPLANT RECIPIENTS

    Nephrology Dialysis Transplantation, 2017

    DOI 10.1093/ndt/gfx158.sp788 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  32. FRI0479 Efficacy of Colchicine and IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever: A Retrospective Analysis

    Annals of the Rheumatic Diseases, 2016

    DOI 10.1136/annrheumdis-2016-eular.5360 3 citations (OpenAlex) Source: OpenAlex